Institutions / Soleus Capital Management, L.P.

Soleus Capital Management, L.P.

CIK 1802630 · Institution · as of Dec 31, 2025
Portfolio value
$2.36B
Positions
94
As of
Dec 31, 2025

Top holdings

Dec 31, 2025View all 94 →
CompanyClassValueShares% of portfolio
Krystal Biotech, Inc.$232.01M941,0599.8%
Celcuity Inc.CELCCommon Stock$180.36M1,808,2587.7%
NovoCure Ltd$110.30M8,530,6654.7%
Praxis Precision Medicines, Inc.$106.98M362,9664.5%
TG Therapeutics Inc$93.58M3,139,3124.0%
Dexcom Inc$86.09M1,297,0943.7%
BioMarin Pharmaceutical Inc$78.45M1,320,0003.3%
Globus Medical Inc$77.44M887,0003.3%
Beta Bionics, Inc.$77.23M2,534,5653.3%
Amicus Therapeutics Inc$74.15M5,207,2843.1%
Twist Bioscience Corp$59.06M1,861,8022.5%
Organogenesis Holdings Inc.ORGOCommon Stock$51.73M9,985,9512.2%
Syndax Pharmaceuticals Inc$47.21M2,247,1102.0%
Mirum Pharmaceuticals, Inc.$45.31M573,6141.9%
Insulet Corp$42.64M150,0001.8%
NeuroPace Inc$41.74M2,703,2081.8%
Axogen, Inc.$39.50M1,206,8551.7%
Ani Pharmaceuticals Inc$38.38M486,2431.6%
Alkermes plc.$37.00M1,322,3641.6%
LivaNova PLC$34.92M567,5001.5%
Gsk PLC$31.34M639,0001.3%
Geron Corp$30.74M23,290,0001.3%
United Therapeutics Corp$29.23M60,0001.2%
Immunovant, Inc.IMVTCommon Stock$28.22M1,110,0001.2%
Vaxcyte, Inc.$28.10M608,9581.2%

Activity

Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.
No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.